TY - JOUR T1 - Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India JF - medRxiv DO - 10.1101/2021.06.02.21258076 SP - 2021.06.02.21258076 AU - Mahesh S Dhar AU - Robin Marwal AU - VS Radhakrishnan AU - Kalaiarasan Ponnusamy AU - Bani Jolly AU - Rahul C. Bhoyar AU - Saman Fatihi AU - Meena Datta AU - Priyanka Singh AU - Uma Sharma AU - Rajat Ujjainia AU - Salwa Naushin AU - Nitin Bhateja AU - Mohit Kumar Divakar AU - Viren Sardana AU - Manoj K Singh AU - Mohamed Imran AU - Vigneshwar Senthivel AU - Ranjeet Maurya AU - Neha Jha AU - Priyanka Mehta AU - Mercy Rophina AU - VR Arvinden AU - Urmila Chaudhary AU - Lipi Thukral AU - Rajesh Pandey AU - Debasis Dash AU - Mohammed Faruq AU - Hemlata Lall AU - Hema Gogia AU - Preeti Madan AU - Sanket Kulkarni AU - Himanshu Chauhan AU - Shantanu Sengupta AU - Sandhya Kabra AU - The Indian SARS-CoV-2 Genomics Consortium (INSACOG) AU - Sujeet K Singh AU - Anurag Agrawal AU - Partha Rakshit Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/03/2021.06.02.21258076.abstract N2 - In April 2021, after successfully enduring three waves of the SARS-CoV2 pandemic in 2020, and having reached population seropositivity of about 50%, Delhi, the national capital of India was overwhelmed by the fourth wave. Here, we trace viral, host, and social factors contributing to the scale and exponent of the fourth wave, when compared to preceding waves, in an epidemiological context. Genomic surveillance data from Delhi and surrounding states shows an early phase of the upsurge driven by the entry of the more transmissible B.1.1.7 variant of concern (VOC) into the region in January, with at least one B.1.1.7 super spreader event in February 2021, relatable to known mass gatherings over this period. This was followed by seeding of the B.1.617 VOC, which too is highly transmissible, with rapid expansion of B.1.617.2 sub-lineage outpacing all other lineages. This unprecedented growth of cases occurred in the background of high seropositivity, but with low median neutralizing antibody levels, in a serially sampled cohort. Vaccination breakthrough cases over this period were noted, disproportionately related to VOC in sequenced cases, but usually mild. We find that this surge of SARS-CoV2 infections in Delhi is best explained by the introduction of a new highly transmissible VOC, B.1.617.2, with likely immune-evasion properties; insufficient neutralizing immunity, despite high seropositivity; and social behavior that promoted transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport from Ministry of Health and Family Welfare, Council of Scientific and Industrial Research, and Department of Biotechnology, India, is acknowledged.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SARSCoV2 genomic study was approved by the NCDC Ethics Review Committee vide approval 2020/NERC/14. The serology study was approved by the Institutional Human Ethics Committee of CSIRIGIB vide approval CSIR IGIB/IHEC/2019_20 All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data is being continuously uploaded on the GISAID. https://www.gisaid.org/ ER -